Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05221281
Other study ID # 1000078476
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 25, 2022
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Transition in care is defined as the "purposeful and planned movement of adolescents and young adults with a chronic medical condition from pediatric to adult-oriented healthcare systems/care providers." Currently, there is no Level 1 evidence of an intervention to improve the care of transitioning adolescents and young adults (AYAs) with inflammatory bowel disease (IBD). The development of a transition program using a biopsychosocial approach will improve the standards for healthcare delivery to transitioning IBD patients. This is a protocol for a structured randomized controlled trial (RCT) to assess the efficacy and impact of a multimodal intervention focused on improving patient function, transition readiness and outcomes among AYA patients with IBD being cared for at pediatric centers in Canada. Methods: This multi-center RCT is a type 1 hybrid effectiveness-implementation trial to evaluate effectiveness of the intervention and how it can be implemented more widely after the trial. We will include patients aged 16.0 to 17.5 years. The intervention program consists of 4 core components: 1) individualized assessment, 2) transition navigator, 3) virtual patient skills-building with a focus on building resilience, self-management and self-efficacy, and 4) a virtual structured education program. The control group will undergo standard-of-care defined by each participating center. The primary outcome will be the IBD Disability Index, a validated measure to assess patient functioning. Secondary outcomes include transition readiness, anxiety and depression scales, and health service utilization rates. Additionally, we will identify the effectiveness of an evidence-based implementation approach and related barriers and facilitators for the intervention program. Discussion: The type 1 hybrid effectiveness-implementation design will allow us to develop a feasible, sustainable, and acceptable final intervention model. The intervention will consist of modules that can be accessed in an online, virtual platform. The implementation will not depend on individual hospital resources, allowing centralization of interventions and funding. The authors anticipate that the main study limitation will relate to study subjects not completely adhering to every component of the intervention, which will be evaluated and addressed using the implementation science approach.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date December 31, 2025
Est. primary completion date July 1, 2025
Accepts healthy volunteers No
Gender All
Age group 16 Years to 17 Years
Eligibility Inclusion Criteria: - Aged 16-17.5 years - Diagnosed with IBD diagnosed using standard criteria - Ability to speak/read English at a functional (Grade 8) level - Intention to reside in Canada after transfer to adult care - Ability to use a smartphone or personal computer for the virtual intervention Exclusion Criteria: - Do not speak English fluently - Intention to leave Canada after graduation from high school

Study Design


Intervention

Behavioral:
Multimodal intervention consisting of four core components
Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation. Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support. Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase. Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators.
Standard of care
The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions: A written letter explaining the goals of transition to the patient and family. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51 Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee). Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53 The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below.

Locations

Country Name City State
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Canada The Hospital for Sick Children Toronto Ontario
Canada BC Children's Hospital Vancouver British Columbia

Sponsors (5)

Lead Sponsor Collaborator
The Hospital for Sick Children Crohn's and Colitis Canada, The Canadian Children Inflammatory Bowel Disease Network: A Partnership with the CH.I.L.D. Foundation, The CH.I.L.D. Foundation - Children with Intestinal & Liver Disorders, The Leona M. and Harry B. Helmsley Charitable Trust

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary IBD Disability Index (IBD-DI) Ordinal variable that measures participant functioning as the primary outcome. IBD-DI was selected as a validated measure of overall disability, functioning, and health. The primary outcome will be measured 3 years after enrollment. 3 years
Secondary Transition Readiness Assessment Questionnaire (TRAQ) Transition Readiness 3 years
Secondary Transition Readiness Assessment Questionnaire (TRAQ) Transition Readiness Up to 24 months (at time of transfer to adult care)
Secondary Transition Success Scores (TSS) Transition Readiness 3 years
Secondary Transition Success Scores (TSS) Transition Readiness Up to 24 months (at time of transfer to adult care)
Secondary Pediatric IBD INTERMED Biopsychosocial Risk Profile 3 years
Secondary Pediatric IBD INTERMED Biopsychosocial Risk Profile Up to 24 months (at time of transfer to adult care)
Secondary IBD-KID2 Disease-related knowledge 3 years
Secondary IBD-KID2 Disease-related knowledge Up to 24 months (at time of transfer to adult care)
Secondary IBDQ-32 Quality of life 3 years
Secondary IBDQ-32 Quality of life Up to 24 months (at time of transfer to adult care)
Secondary IBD Self-Efficacy Scale - Adolescent (IBD-SES-A) Self-Efficacy 3 years
Secondary IBD Self-Efficacy Scale - Adolescent (IBD-SES-A) Self-Efficacy Up to 24 months (at time of transfer to adult care)
Secondary Physician Global Assessment (PGA) Physician assessment of disease activity 3 years
Secondary Physician Global Assessment (PGA) Physician assessment of disease activity Up to 24 months (at time of transfer to adult care)
Secondary Fecal calprotectin Measure of gut inflammation 3 years
Secondary Modified Harvey-Bradshaw Index (HBI) for Crohn's disease Disease activity in Crohn's disease patients 3 years
Secondary Modified Harvey-Bradshaw Index (HBI) for Crohn's disease Disease activity in Crohn's disease patients Up to 24 months (at time of transfer to adult care)
Secondary Pediatric Ulcerative Colitis Activity Index (PUCAI) Disease activity in ulcerative colitis patients 3 years
Secondary Pediatric Ulcerative Colitis Activity Index (PUCAI) Disease activity in ulcerative colitis patients Up to 24 months (at time of transfer to adult care)
Secondary Emergency department visit after 18th birthday (yes/no) Health services utilization 3 years
Secondary Number of emergency department visits after 18th birthday Health services utilization 3 years
Secondary Hospitalization after 18th birthday (yes/no) Health services utilization 3 years
Secondary Number of outpatient visits to a gastroenterologist after 18th birthday Health services utilization 3 years
Secondary IBD Disability Index (IBD-DI) Ordinal variable that measures participant functioning as the primary outcome. IBD-DI was selected as a validated measure of overall disability, functioning, and health. Up to 24 months (at time of transfer to adult care)
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2